BCL2 and breast carcinoma: Anticancer activity of plumbagin against human breast cancer cells, including inhibition of cell growth and apoptosis induction, was shown to be partly due to the inhibition of the NF-kB/Bcl-2 pathway.[13] Interestingly, throughout the combination studies on MST-312 and plumbagin treatment, it was found that plumbagin exerts efficient anti-cancer effects on highly resistant and metastatic MDA-MB-231 breast cancer cells.